

IUCLS 2024 Draft Agenda
 Times for each day are in Central Time

Friday, April 19, 2024	Interprofessional Session
7:00 – 8:00 AM	Registration, Breakfast & Exhibits
8:00 – 8:15 AM	Welcome, Introductions and Pre-session ARS
8:15 – 9:25 AM	Moderator: Kirk Cahill, MD Mini Symposium on Bispecifics
	8:15 – 8:45 AM: Overview of Bispecific Antibodies: Comparing and Contrasting Current and Emerging Agents <i>Tara McCabe, APN</i> 8:45 – 9:15 AM: Practical Aspects of Bispecifics: Supportive Care Strategies <i>Kaitlin Kelly, PharmD, BCOP</i> 9:15 – 9:25 AM: Panel Discussion, Q&A, and Post-session ARS
9:25 – 9:55 AM	9:25 – 9:40 AM: Supportive Care for Patients with HL Receiving Immunotherapy: Differentiating Checkpoint Inhibitors vs Antibody-Drug Conjugates <i>Rebecca Follenweider, BSN, RN, OCN</i> 9:40 – 9:55 AM: Panel Discussion with Cases <i>Rebecca Follenweider, BSN, RN, OCN, Kaitlin Kelly, PharmD, BCOP, and Grace Rivera, MSN, AGPCNP-BC</i>
9:55 – 10:15 AM	Break & Exhibits
10:15 – 11:30 AM	Moderator: Neha Mehta-Shah, MD, MSCI Mini Symposium on Advanced Technology in Cancer Care
	10:15 – 10:20 AM: Pre-session ARS 10:20 – 10:50 AM: Artificial Intelligence and Computational Oncology <i>Frederick Howard, MD</i> 10:50 – 11:20 AM: Primer on CRISPR and its Impact on Cancer Research and Treatment <i>Justin Kline, MD</i> 11:20 – 11:30 AM: Panel Discussion, Q&A, and Post-session ARS
11:30 AM – 1:00 PM	Lunch & Exhibits

General Session Day 1

Friday, April 19, 2024	General Session
1:00 – 1:05 PM	Welcome and Introductions <i>Sonali Smith, MD, FASCO</i>
1:05 – 2:30 PM	Moderator: Sonali Smith, MD, FASCO Mini Symposium on T-cell Lymphoma 1:05 – 1:10 PM: Pre-session ARS 1:10 – 1:30 PM: Epigenetics in T-cell Lymphoma: Has the Promise Been Fulfilled? <i>Enrica Marchi, MD</i> 1:30 – 1:50 PM: Novel Therapeutics for T-cell Lymphoma and Lessons Learned from the Current Regulatory Environment <i>Swaminathan Iyer, MD</i> 1:50 – 2:10 PM: Management of Advanced CTCL <i>Neha Mehta-Shah, MD, MSCI</i> 2:10 – 2:30 PM: Panel Discussion, Q&A, and Post-session ARS
2:30 – 2:50 PM	Break & Exhibits
2:50 – 4:00 PM	Moderator: Andrew Evens, DO, MBA, MSc Hematopathology Tumor Board <i>Girish Venkataraman, MD; Kirk Cahill, MD; Anamarija Perry, MD</i>
4:00 – 5:20 PM	Moderator: Reem Karmali, MD Mini Symposium on the Management of Bispecifics 4:00 – 4:05 PM: Pre-session ARS 4:05 – 4:25 PM: Bispecifics for LBCL: Focus on Management of Toxicities in the Community <i>Jennifer Crombie, MD</i> 4:25 – 4:45 PM: Bispecifics for FL <i>David Russler-Germain, MD, PhD</i> 4:45 – 5:05 PM: Sequencing of Bispecifics with Other Therapies <i>Elizabeth Budde, MD, PhD</i> 5:05 – 5:20 PM: Panel Discussion Q&A, and Post-session ARS
5:20 PM	Day 1 Wrap Up and Summary <i>Timothy Fenske, MD, MS</i>
5:20 – 6:20 PM	Welcome & Poster Reception with Exhibitors

General Session Day 2

Saturday, April 20	General Session
7:00 – 8:00 AM	Registration, Breakfast & Exhibits
8:00 – 8:05 AM	Welcome and Introductions <i>Neha Mehta-Shah, MD, MSCI</i>
8:05 – 8:25 AM	Moderator: Ruemu Birhiray, MD DEI Keynote Presentation: Implementation of Reducing Barriers to Accessing Lymphoma Care <i>Christopher R. Flowers, MD, MS</i>
8:25 – 8:30 AM	Q&A
8:30 – 10:10 AM	Moderator: Andrew Evens, DO, MBA, MSc Mini Symposium on Hodgkin Lymphoma 8:30 – 8:35 AM: Pre-session ARS 8:35 – 8:55 AM: Ensuring the Progress in Hodgkin Lymphoma Applies to All Patients <i>Justine Kahn, MD</i> 8:55 – 9:15 AM: Are Checkpoint Inhibitors the Standard of Care for Frontline Hodgkin Lymphoma? <i>Boyu Hu, MD</i> 9:15 – 9:35 AM: What is the Standard of Care in Second Line Hodgkin Lymphoma? <i>Sarah Rutherford, MD</i> 9:35 – 9:55 AM: Who Benefits the Most from Radiation in Hodgkin Lymphoma? <i>Chelsea C. Pinnix, MD, PhD</i> 9:55 – 10:10 AM: Panel Discussion, Q&A, and Post-session ARS
10:10 – 10:30 AM	Break & Exhibits
10:30 – 12:10 PM	Moderators: Timothy Fenske, MD, MS & Leo Gordon, MD/Andrew Evens (backup) “Duel” Symposium: Measuring MRD is the Standard of Care in CLL 10:30 – 10:35 AM: Pre-session ARS 10:35 AM: Yes <i>Joanna Rhodes, MD, MSCE</i> 10:55 AM: No <i>Jacob Soumerai, MD</i> “Dual” Symposium: Special Considerations in Treating Patients with Lymphoma – Impact of Patient Age 11:15 AM: AYA Patients <i>Susan Parsons, MD</i> 11:35 AM: Elderly/Older Patients <i>Stefano Luminari, MD</i> 11:55 AM– 12:10 PM: Panel Discussion, Q&A, and Post-session ARS
12:10 – 1:25 PM	Lunch & Exhibits
1:25 – 2:25 PM	Moderator: Sonali Smith, MD, FASCO Keynote Presentation: The Evolution and State of Lymphoma Research <i>Andrew Zelenetz, MD, PhD</i>
2:25 – 3:45 PM	Moderator: Vaishalee Kenkre, MD Mini Symposium on Small Molecule Inhibitors in Lymphoma

	<p>2:25 – 2:30 PM: Presession ARS</p> <p>2:30 – 2:50 PM: Targeting BTK: Inhibitors vs Degraders <i>Adam Kittai, MD</i></p> <p>2:50 – 3:10 PM: PI3K: Is Targeting This Pathway Still Valuable? <i>Changchun Deng, MD, PhD</i></p> <p>3:10 – 3:30 PM: The Next Frontier of Targeted Therapy in Lymphoma <i>Kami J. Maddocks, MD</i></p> <p>3:30 – 3:45 PM: Panel Discussion, Q&A, and Postsession ARS</p>
3:45 – 3:55 PM	<p>Moderator: Timothy Fenske, MD, MS</p> <p>Summary and Best of IUCLS</p> <p><i>Symposium Co-Chairs</i></p>
3:55 PM	Adjourn